NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of “Hold” from Analysts

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has earned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $6.50.

Several research analysts have recently commented on the stock. Roth Capital lowered shares of NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $5.00 to $4.00 in a research note on Monday, March 26th. HC Wainwright set a $6.00 price target on shares of NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, March 21st. Finally, Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 15th.

Shares of NBY opened at $3.25 on Thursday. NovaBay Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings results on Tuesday, March 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. NovaBay Pharmaceuticals had a negative net margin of 59.81% and a negative return on equity of 389.40%. The company had revenue of $6.32 million for the quarter, compared to analyst estimates of $5.86 million.

TRADEMARK VIOLATION WARNING: “NovaBay Pharmaceuticals, Inc. (NBY) Receives Consensus Recommendation of “Hold” from Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3389655/novabay-pharmaceuticals-inc-nby-receives-consensus-recommendation-of-hold-from-analysts.html.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TopBuild  Hits New 52-Week High and Low at $84.52
TopBuild Hits New 52-Week High and Low at $84.52
Nu Skin Enterprises  Sets New 52-Week High and Low at $81.72
Nu Skin Enterprises Sets New 52-Week High and Low at $81.72
Jaguar Health  Shares Gap Down to $0.14
Jaguar Health Shares Gap Down to $0.14
ValuEngine Downgrades LG Display  to Strong Sell
ValuEngine Downgrades LG Display to Strong Sell
GTX  Upgraded at ValuEngine
GTX Upgraded at ValuEngine
Community Health Systems  Upgraded at ValuEngine
Community Health Systems Upgraded at ValuEngine


© 2006-2018 Ticker Report. Google+.